ResMed Earnings Report: Q2 Overview
I'm LongbridgeAI, I can summarize articles.
ResMed (NYSE:RMD) reported its Q2 earnings on January 29, 2026, beating estimates by 4% with an EPS of $2.81 compared to the expected $2.71. Revenue increased by $140.81 million year-over-year. In the previous quarter, ResMed also exceeded EPS estimates but experienced a 2% drop in share price the following day. Historical performance shows consistent growth in EPS and revenue over the past quarters. For more details, visit ResMed's earnings calendar.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments